74 results on '"Perfect JR"'
Search Results
2. New anticancer therapeutics impact fungal pathobiology, infection dynamics, and outcome.
- Author
-
Palmucci JR, Messina JA, Tenor JL, and Perfect JR
- Subjects
- Mycoses, Antineoplastic Agents
- Abstract
Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2023
- Full Text
- View/download PDF
3. The current state of Clinical Mycology in Eastern and South-Eastern Europe.
- Author
-
Driemeyer C, Falci DR, Hoenigl M, Cornely OA, Chakrabarti A, Gangneux JP, Segal E, Jürna-Ellam M, Matos T, Meis JF, Perfect JR, Arsenijevic VA, Mares M, Serban DE, and Pasqualotto AC
- Subjects
- Animals, Antifungal Agents therapeutic use, Cross-Sectional Studies, Europe, Europe, Eastern, Humans, Mycology, Mycoses diagnosis, Mycoses drug therapy, Mycoses microbiology, Mycoses veterinary
- Abstract
The ability of medical centers in Eastern and South-Eastern Europe to diagnose and treat fungal infections remains unknown. In order to investigate that, here we conducted a cross-sectional online survey, released at both The International Society for Human & Animal Mycology (ISHAM) and European Confederation of Medical Mycology (ECMM) websites. A total of 31 institutions responded to the questionnaire. Most centers (87.1%, n = 27) had access to Aspergillus spp. ELISA galactomannan testing as well as to Cryptococcus spp. antigen testing (83.9%, n = 26). Serological tests were mostly available for Aspergillus species (80.6%, n = 25); and most institutions reported access to mold-active antifungal drugs (83.9%; n = 26), but 5-flucytosine was available to only 29% (n = 9) of the participant centers. In conclusion, this study represents the first attempt to document the strengths and limitations of the Eastern and South-Eastern European region for diagnosing and treating fungal diseases., Lay Summary: Our article is about the availability of diagnostic and treatments tools related to fungal infections in the countries of Eastern and South-Eastern region. Surveys like these are important to understand the gaps and point towards the fungal infections as a global health issue., (© The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2022
- Full Text
- View/download PDF
4. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.
- Author
-
Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrisey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, and Pappas PG
- Subjects
- Antifungal Agents therapeutic use, Consensus, Humans, Immunocompromised Host, Invasive Fungal Infections diagnosis, Invasive Fungal Infections drug therapy, Mycoses diagnosis, Mycoses drug therapy, Mycoses epidemiology, Neoplasms drug therapy
- Abstract
Background: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential., Methods: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved., Results: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses., Conclusions: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2020
- Full Text
- View/download PDF
5. Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium.
- Author
-
Johnson MD, Lewis RE, Dodds Ashley ES, Ostrosky-Zeichner L, Zaoutis T, Thompson GR, Andes DR, Walsh TJ, Pappas PG, Cornely OA, Perfect JR, and Kontoyiannis DP
- Subjects
- Antifungal Agents pharmacology, Clinical Competence, Drug Monitoring standards, Drug Prescriptions standards, Drug Resistance, Fungal, Humans, Inappropriate Prescribing prevention & control, Mycoses microbiology, Antifungal Agents therapeutic use, Antimicrobial Stewardship standards, Evidence-Based Medicine standards, Mycoses drug therapy, Practice Guidelines as Topic
- Abstract
In recent years, the global public health community has increasingly recognized the importance of antimicrobial stewardship (AMS) in the fight to improve outcomes, decrease costs, and curb increases in antimicrobial resistance around the world. However, the subject of antifungal stewardship (AFS) has received less attention. While the principles of AMS guidelines likely apply to stewarding of antifungal agents, there are additional considerations unique to AFS and the complex field of fungal infections that require specific recommendations. In this article, we review the literature on AMS best practices and discuss AFS through the lens of the global core elements of AMS. We offer recommendations for best practices in AFS based on a synthesis of this evidence by an interdisciplinary expert panel of members of the Mycoses Study Group Education and Research Consortium. We also discuss research directions in this rapidly evolving field. AFS is an emerging and important component of AMS, yet requires special considerations in certain areas such as expertise, education, interventions to optimize utilization, therapeutic drug monitoring, and data analysis and reporting., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
6. Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda.
- Author
-
Pappas PG, Boulware DR, Kontoyiannis DP, Miceli MH, Ostrosky-Zeichner L, Spec A, Thompson GR, Chen S, and Perfect JR
- Subjects
- Humans, Montana, Organizational Objectives, Biomedical Research organization & administration, Congresses as Topic, Mycology, Mycoses physiopathology, Research Report
- Published
- 2020
- Full Text
- View/download PDF
7. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
- Author
-
Perfect JR, Cornely OA, Heep M, Ostrosky-Zeichner L, Mullane KM, Maher R, Croos-Dabrera R, Lademacher C, Engelhardt M, Chen C, and Marty FM
- Subjects
- Adult, Antifungal Agents administration & dosage, Antifungal Agents adverse effects, Fungi drug effects, Humans, Immunocompromised Host, Middle Aged, Mucormycosis drug therapy, Mycoses microbiology, Nitriles administration & dosage, Nitriles adverse effects, Pyridines administration & dosage, Pyridines adverse effects, Rare Diseases drug therapy, Rare Diseases microbiology, Renal Insufficiency complications, Triazoles administration & dosage, Triazoles adverse effects, Antifungal Agents therapeutic use, Invasive Fungal Infections drug therapy, Invasive Pulmonary Aspergillosis drug therapy, Mycoses drug therapy, Nitriles therapeutic use, Pyridines therapeutic use, Randomized Controlled Trials as Topic, Renal Insufficiency microbiology, Triazoles therapeutic use
- Abstract
Invasive fungal disease (IFD) confers a substantial risk for morbidity and mortality to immunocompromised patients. Invasive aspergillosis (IA) is the most common IFD caused by moulds but the prevalence of other rare mould diseases, such as mucormycosis, hyalohyphomycosis and phaeohyphomycosis, may be increasing. Treatments are available for IA, but evidence to support efficacy and safety of antifungal agents for rare IFDs, or for IFDs in special patient populations, is limited or lacking. The VITAL trial was conducted to assess the efficacy and safety of isavuconazole for the treatment of patients with IA and renal impairment, or with IFDs caused by rare moulds, yeasts or dimorphic fungi. These patients stand to benefit most from a new treatment option but are unlikely to be included in a randomised, controlled trial. In this article, we review the challenges faced in the design and conduct of the VITAL trial. We also review the findings of VITAL, which included evidence of the efficacy and safety of isavuconazole. Finally, we consider the importance of trials such as VITAL to inform therapeutic decision making for clinicians faced with the challenge of treating patients with rare IFDs and as one paradigm of how to determine efficacy and safety of new drugs for rare and resistant infections without a suitable comparator., (© 2018 The Authors. Mycoses Published by Blackwell Verlag GmbH.)
- Published
- 2018
- Full Text
- View/download PDF
8. Fungi that Infect Humans.
- Author
-
Köhler JR, Hube B, Puccia R, Casadevall A, and Perfect JR
- Subjects
- Ascomycota classification, Ascomycota pathogenicity, Basidiomycota classification, Basidiomycota pathogenicity, Biological Evolution, Body Temperature, Entomophthorales classification, Entomophthorales pathogenicity, Host-Pathogen Interactions immunology, Humans, Immunity, Innate immunology, Immunocompromised Host, Mucorales classification, Mucorales pathogenicity, Mycetoma microbiology, Mycoses immunology, Opportunistic Infections microbiology, Phylogeny, Virulence, Fungi classification, Fungi pathogenicity, Host-Pathogen Interactions physiology, Mycoses microbiology
- Abstract
Fungi must meet four criteria to infect humans: growth at human body temperatures, circumvention or penetration of surface barriers, lysis and absorption of tissue, and resistance to immune defenses, including elevated body temperatures. Morphogenesis between small round, detachable cells and long, connected cells is the mechanism by which fungi solve problems of locomotion around or through host barriers. Secretion of lytic enzymes, and uptake systems for the released nutrients, are necessary if a fungus is to nutritionally utilize human tissue. Last, the potent human immune system evolved in the interaction with potential fungal pathogens, so few fungi meet all four conditions for a healthy human host. Paradoxically, the advances of modern medicine have made millions of people newly susceptible to fungal infections by disrupting immune defenses. This article explores how different members of four fungal phyla use different strategies to fulfill the four criteria to infect humans: the Entomophthorales, the Mucorales, the Ascomycota, and the Basidiomycota. Unique traits confer human pathogenic potential on various important members of these phyla: pathogenic Onygenales comprising thermal dimorphs such as Histoplasma and Coccidioides ; the Cryptococcus spp. that infect immunocompromised as well as healthy humans; and important pathogens of immunocompromised patients- Candida , Pneumocystis , and Aspergillus spp. Also discussed are agents of neglected tropical diseases important in global health such as mycetoma and paracoccidiomycosis and common pathogens rarely implicated in serious illness such as dermatophytes. Commensalism is considered, as well as parasitism, in shaping genomes and physiological systems of hosts and fungi during evolution.
- Published
- 2017
- Full Text
- View/download PDF
9. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.
- Author
-
Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, Maher R, Lee M, Kovanda L, Engelhardt M, Vazquez JA, Cornely OA, and Perfect JR
- Subjects
- Adult, Aged, Antifungal Agents adverse effects, Blastomycosis drug therapy, Blastomycosis microbiology, Coccidioidomycosis drug therapy, Coccidioidomycosis microbiology, Cryptococcosis drug therapy, Cryptococcosis microbiology, Female, Histoplasmosis drug therapy, Histoplasmosis microbiology, Humans, Male, Middle Aged, Mycoses microbiology, Nitriles adverse effects, Paracoccidioidomycosis drug therapy, Paracoccidioidomycosis microbiology, Pyridines adverse effects, Triazoles adverse effects, Young Adult, Antifungal Agents pharmacology, Mycoses drug therapy, Nitriles pharmacology, Pyridines pharmacology, Triazoles pharmacology
- Abstract
Background: Invasive fungal diseases (IFD) caused by Cryptococcus and dimorphic fungi are associated with significant morbidity and mortality. Isavuconazole (ISAV) is a novel, broad-spectrum, triazole antifungal agent (IV and by mouth [PO]) developed for the treatment of IFD. It displays potent activity in vitro against these pathogens and in this report we examine outcomes of patients with cryptococcosis or dimorphic fungal infections treated with ISAV., Methods: The VITAL study was an open-label nonrandomized phase 3 trial conducted to evaluate the efficacy and safety of ISAV treatment in management of rare IFD. Patients received ISAV 200 mg 3 times daily for 2 days followed by 200 mg once-daily (IV or PO). Proven IFD and overall response at end of treatment (EOT) were determined by an independent, data-review committee. Mortality and safety were also assessed., Results: Thirty-eight patients received ISAV for IFD caused by Cryptococcus spp. (n = 9), Paracoccidioides spp. (n = 10), Coccidioides spp. (n = 9), Histoplasma spp. (n = 7) and Blastomyces spp. (n = 3). The median length of therapy was 180 days (range 2-331 days). At EOT 24/38 (63%) patients exhibited a successful overall response. Furthermore, 8 of 38 (21%) had stable IFD at the end of therapy without progression of disease, and 6 (16%) patients had progressive IFD despite this antifungal therapy. Thirty-three (87%) patients experienced adverse events., Conclusions: ISAV was well tolerated and demonstrated clinical activity against these endemic fungi with a safety profile similar to that observed in larger studies, validating its broad-spectrum in vitro activity and suggesting it may be a valuable alternative to currently available agents., Clinical Trials Registration: NCT00634049., (© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2016
- Full Text
- View/download PDF
10. "Is there an emerging need for new antifungals?".
- Author
-
Perfect JR
- Subjects
- Animals, Fungi drug effects, Fungi isolation & purification, Humans, Mycoses microbiology, Antifungal Agents pharmacology, Drug Design, Mycoses drug therapy
- Published
- 2016
- Full Text
- View/download PDF
11. Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients.
- Author
-
Perfect JR, Hachem R, and Wingard JR
- Subjects
- Aspergillosis etiology, Aspergillosis prevention & control, Candidiasis etiology, Candidiasis prevention & control, Humans, Mycoses etiology, Mycoses microbiology, Risk Assessment, Antifungal Agents therapeutic use, Bone Marrow Transplantation, Leukemia, Myeloid, Acute complications, Mycoses epidemiology, Mycoses prevention & control, Neoplasms complications
- Abstract
Changes in antineoplastic treatments and transplant practices are driving shifts in the epidemiology of invasive fungal diseases (IFDs). Patients with acute myelogenous leukemia (AML) and those undergoing bone marrow transplant (BMT) are at greatest risk for contracting IFDs. Unfortunately, there are few large population studies that can be used to track trends and help us to better understand why certain individuals within recognized high-risk groups are at greater risks than others for contracting IFDs. The growing use of antifungals in prophylaxis and treatment influences which species will cause an IFD as well as the resistance patterns of these fungi. On the one hand, antifungal prophylaxis has mitigated, but not eliminated, the threat of candidiasis. Furthermore, prophylaxis trials have shown trends of reduced aspergillosis in BMT patients; however, no survival benefits were seen, and 1 trial indicated a lower rate of aspergillosis and survival benefits in patients with AML. Future prophylaxis trials should reduce the heterogeneity of risk in study participants in order to better assess benefit; these trials should also incorporate fungal biomarkers into their design. The threat of emerging fungal resistance in prophylaxis strategies is real and must be monitored., (© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2014
- Full Text
- View/download PDF
12. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study.
- Author
-
Kung HC, Johnson MD, Drew RH, Saha-Chaudhuri P, and Perfect JR
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Female, Fluconazole adverse effects, Hematologic Neoplasms complications, Hematologic Neoplasms pathology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Mycoses complications, Mycoses pathology, Retrospective Studies, Treatment Outcome, Triazoles adverse effects, United States, Fluconazole administration & dosage, Hematologic Neoplasms drug therapy, Mycoses drug therapy, Triazoles administration & dosage
- Abstract
In preventing invasive fungal disease (IFD) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS), clinical trials demonstrated efficacy of posaconazole over fluconazole and itraconazole. However, effectiveness of posaconazole has not been investigated in the United States in real-world setting outside the environment of controlled clinical trial. We performed a single-center, retrospective cohort study of 130 evaluable patients ≥18 years of age admitted to Duke University Hospital between 2004 and 2010 who received either posaconazole or fluconazole as prophylaxis during first induction or first reinduction chemotherapy for AML or MDS. The primary endpoint was possible, probable, or definite breakthrough IFD. Baseline characteristics were well balanced between groups, except that posaconazole recipients received reinduction chemotherapy and cytarabine more frequently. IFD occurred in 17/65 (27.0%) in the fluconazole group and in 6/65 (9.2%) in the posaconazole group (P = 0.012). Definite/probable IFDs occurred in 7 (10.8%) and 0 patients (0%), respectively (P = 0.0013). In multivariate analysis, fluconazole prophylaxis and duration of neutropenia were predictors of IFD. Mortality was similar between groups. This study demonstrates superior effectiveness of posaconazole over fluconazole as prophylaxis of IFD in AML and MDS patients. Such superiority did not translate to reductions in 100-day all-cause mortality., (© 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
13. Recent advances in the treatment of life-threatening, invasive fungal infections.
- Author
-
Drew RH, Townsend ML, Pound MW, Johnson SW, and Perfect JR
- Subjects
- Animals, Humans, Antifungal Agents therapeutic use, Mycoses drug therapy
- Abstract
Introduction: Invasive fungal infections (IFIs) pose significant morbidity and are often life-threatening to many high-risk patients. Timely diagnosis and treatment of these infections with optimal therapy is imperative., Areas Covered: Advances have been made in diagnostic biomarkers such as peptide nucleic acid fluorescent in situ hybridization, β-D-glucan and galactomannan, although more research is needed in this area to assist with both diagnosis and monitoring for improvement of IFI management. Novel antifungal agents (azole antifungals and echinocandins) are being investigated that have activity against Candida spp. and Aspergillus spp. Optimizing the pharmacodynamics (PD) of our current antifungal therapies through such strategies as continuous infusion of amphotericin B and dose escalation of echinocandins and liposomal formulations of amphotericin B have also been investigated with mixed results. Therapeutic drug monitoring (TDM) shows promise as evident from data with such agents as flucytosine, itraconazole, voriconazole and posaconazole., Expert Opinion: The goal for the future of biomarkers in IFIs will be to have excellent sensitivity and specificity to ideally identify a particular fungus causing the infection or eliminate its existence to prevent unnecessary costs, resistance and antifungal usage. In addition, further developments of new antifungals are needed and judicious use of the current regimens needs to be optimized through antifungal PD properties and TDM.
- Published
- 2013
- Full Text
- View/download PDF
14. Real-time treatment guidelines: considerations during the Exserohilum rostratum outbreak in the United States.
- Author
-
Pappas PG, Kontoyiannis DP, Perfect JR, and Chiller TM
- Subjects
- Animals, Humans, Mycoses drug therapy
- Published
- 2013
- Full Text
- View/download PDF
15. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease.
- Author
-
O'Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston AA, Perfect JR, and Papadopoulos G
- Subjects
- Antifungal Agents economics, Cost-Benefit Analysis, Fluconazole economics, Graft vs Host Disease complications, Humans, Itraconazole economics, Models, Economic, Mycoses economics, Severity of Illness Index, Transplantation, Homologous, United States, Antifungal Agents therapeutic use, Fluconazole therapeutic use, Itraconazole therapeutic use, Mycoses prevention & control
- Abstract
Purpose: The results of a pharmacoeconomic study of the cost-effectiveness of posaconazole versus fluconazole in preventing invasive fungal infections (IFIs) in patients with graft-versus-host disease (GVHD) are reported., Methods: The results of a randomized clinical trial suggested that posaconazole may be as effective as fluconazole for the prevention of IFIs in recipients of allogeneic cell transplants who develop severe GVHD and that posaconazole may be superior to fluconazole in reducing IFI-related deaths. Using published data from that trial and data from secondary sources, an economic model was developed to estimate the costs, IFIs avoided, and life-years saved with posaconazole versus fluconazole therapy. The results of the modeled 112-day treatment simulation were extrapolated to a lifetime horizon., Results: In the modeled simulation, posaconazole therapy was associated with a lower probability of IFI development (0.05 versus 0.09), increased discounted life-years (7.87 life-years versus 7.66 life-years), and higher discounted costs per patient ($8,860 versus $5,710 in 2006 U.S. dollars) relative to fluconazole therapy. The estimated incremental cost-effectiveness of posaconazole versus fluconazole for IFI prophylaxis was $85,300 per IFI avoided and $15,300 per life-year saved. A sensitivity analysis indicated a 90% probability that the use of posaconazole for this purpose would be cost-effective at a threshold of $50,000 per life-year saved., Conclusion: Posaconazole is in the range of currently accepted criteria for cost- effectiveness relative to fluconazole for the prevention of IFIs among patients with GVHD.
- Published
- 2012
- Full Text
- View/download PDF
16. Invasive mycoses: evolving challenges and opportunities in antifungal therapy. Introduction.
- Author
-
Perfect JR
- Subjects
- Antifungal Agents adverse effects, Antifungal Agents therapeutic use, Biomarkers blood, Delayed Diagnosis, Drug Resistance, Fungal, Humans, Immune Reconstitution Inflammatory Syndrome diagnosis, Liver drug effects, Microbial Sensitivity Tests, beta-Glucans blood, Mycoses blood, Mycoses diagnosis, Mycoses drug therapy, Mycoses immunology
- Published
- 2012
- Full Text
- View/download PDF
17. The impact of the host on fungal infections.
- Author
-
Perfect JR
- Subjects
- Adult, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Child, Preschool, Cryptococcosis immunology, Cryptococcus neoformans, Diagnosis, Differential, Female, Fusariosis immunology, Humans, Immune Reconstitution Inflammatory Syndrome immunology, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents adverse effects, Kidney Transplantation, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Male, Middle Aged, Mycoses diagnosis, Mycoses drug therapy, Neutropenia chemically induced, Neutropenia immunology, Opportunistic Infections diagnosis, Pregnancy, Risk Factors, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antifungal Agents therapeutic use, Immune Reconstitution Inflammatory Syndrome diagnosis, Immunocompromised Host, Mycoses immunology, Mycoses microbiology, Opportunistic Infections immunology, Opportunistic Infections microbiology
- Abstract
Outcomes of fungal infections in immunocompromised individuals depend on a complex interplay between host and pathogen factors, as well as treatment modalities. Problems occur when host responses to an infection are either too weak to effectively help eradicate the pathogen, or when they become too strong and are associated with host damage rather than protection. Immune reconstitution syndrome (IRS) can be generally defined as a restoration of host immunity in a previously immunosuppressed patient that becomes dysregulated and overly robust, resulting in host damage and sometimes death. IRS associated with opportunistic mycoses presents as new or worsening clinical symptoms or radiographic signs consistent with an inflammatory process that occur during receipt of an appropriate antifungal, and that cannot be explained by a newly acquired infection. Because there are currently no established tests or biomarkers for IRS, it can be difficult to distinguish from progression of the original infection, although culture and biomarkers for the fungal pathogen or infection are typically negative during diagnostic workup. IRS was originally characterized in human immunodeficiency virus-infected patients receiving antiretroviral therapy, but has subsequently been described in solid-organ transplant recipients, neutropenic patients, women in the postpartum period, and recipients of tumor necrosis factor-α inhibitor therapy. In each of these cases, recovery of the host's immunity during treatment of an initial infection results in a powerful proinflammatory environment that overshoots and leads to host damage. Optimal management of IRS has not been established at present, but often involves treatment with a corticosteroid or other anti-inflammatory compounds. This article uses a number of patient cases to explore the intricacies of diagnosing and managing a patient with IRS, as well as the other extreme, namely patients who are so immunocompromised without immune recovery that they essentially become breeding grounds for a wide range of opportunistic pathogens, often simultaneously., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
18. Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity).
- Author
-
Perfect JR, Pfaller MA, Ostrosky-Zeichner L, and Kontoyiannis DP
- Subjects
- Antifungal Agents adverse effects, Aspergillus classification, Aspergillus drug effects, Biomarkers, Candida classification, Candida drug effects, Drug Resistance, Fungal, Host-Pathogen Interactions, Humans, Immune Reconstitution Inflammatory Syndrome, Mycoses diagnosis, Mycoses pathology, Risk Factors, Treatment Failure, Antifungal Agents therapeutic use, Mycoses drug therapy
- Published
- 2011
- Full Text
- View/download PDF
19. The economic costs to United States hospitals of invasive fungal infections in transplant patients.
- Author
-
Menzin J, Meyers JL, Friedman M, Korn JR, Perfect JR, Langston AA, Danna RP, and Papadopoulos G
- Subjects
- Adult, Case-Control Studies, Cohort Studies, Cross Infection epidemiology, Female, Hospitals, Humans, Male, Middle Aged, Mycoses epidemiology, Retrospective Studies, Transplantation, United States, Cross Infection economics, Health Care Costs statistics & numerical data, Mycoses economics, Organ Transplantation adverse effects
- Abstract
Background: Patients with a solid organ transplant (SOTs) and hematopoietic stem cell or bone marrow transplants (HSC/BMTs) are at risk of contracting invasive fungal infections (IFIs). Data on the economic burden of IFIs in the United States are sparse., Methods: We conducted a retrospective matched cohort study using the 2004-2005 Healthcare Cost and Utilization Project Nationwide Inpatient Sample. The IFI cohort included patients with ICD-9-CM codes indicating a transplant procedure and an IFI. Matched controls (transplant recipients without an IFI) were chosen based on age (10 year categories), sex, region, hospital type, year, and transplant type. Mortality, length of stay, and costs were reported overall, by transplant type, and by type of mycosis., Results: Nine thousand eight hundred ninety-six patients underwent SOT, and 4661 underwent HSC/BMT. Of these, 80 (0.8%) SOT and 111 (2.4%) HSC/BMT patients had an IFI. Mean age was 41.8 years (SOT) and 37.8 years (HSC/BMT). Aspergillosis was the most common infection. Patients with an IFI had a 5-fold increase in mortality, an additional 19.2 hospital days, and $55,400 in excess costs compared with patients without an IFI. Excess mortality, length of stay, and costs varied by type of transplant and mycosis., Conclusion: The clinical and economic burden of IFIs in transplant recipients may be high., (Copyright © 2011 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
20. Strategies to manage antifungal drug resistance.
- Author
-
Tseng HK and Perfect JR
- Subjects
- Antifungal Agents pharmacology, Fungi isolation & purification, Fungi pathogenicity, Humans, Mycoses epidemiology, Mycoses microbiology, Antifungal Agents therapeutic use, Drug Resistance, Fungal, Fungi drug effects, Mycoses drug therapy
- Abstract
Introduction: Invasive fungal infections continue to cause significant morbidity and mortality in immunocompromised hosts. From more than half a million deaths from cryptococcosis in sub-Saharan Africa to an unchanging death rate from invasive candidiasis, despite three antifungal classes of drugs, insights into better strategies to reduce therapeutic failures or resistance are needed., Areas Covered: This review examines the issues around antifungal drug resistance from both a basic description of the failures and how they are detected to the variety of issues that need to be addressed to help prevent failures for successful management. The reader will gain an understanding of the clinical complexities in this patient population for management of invasive fungal infections. Throughout the review, principles of management are given along with some specific clinical examples to illustrate the issues and frame the knowledge base. From this discussion it is hoped that the clinician can use the insights provided to manage individual patients and find links to the evidence-based material that support its conclusions. Also, this review specifically identifies the limitations of present management and directs clinicians to gather additional information and provide even better treatment strategies., Expert Opinion: Invasive fungal infections are life-threatening complications of serious underlying diseases. Their management can be complicated by both direct and clinical drug resistance and by understanding these possibilities and correcting them; most patients can be successfully managed with present antifungal drugs if the underlying diseases can be controlled.
- Published
- 2011
- Full Text
- View/download PDF
21. The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation.
- Author
-
Alexander BD, Smith PB, Davis RD, Perfect JR, and Reller LB
- Subjects
- Adult, Early Diagnosis, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Proteoglycans, Sensitivity and Specificity, Serum chemistry, Immunocompromised Host, Lung Transplantation, Mycology methods, Mycoses diagnosis, beta-Glucans blood
- Abstract
The Fungitell assay for (1,3)β-D-glucan (BG) detection in serum has been evaluated in patients with invasive fungal infections (IFIs) and healthy controls and for the early diagnosis of IFI in cancer patients. We evaluated the BG assay for the detection of IFI in lung transplant recipients. Serial serum samples were prospectively collected from patients undergoing lung transplants at Duke Hospital. Fungal infections were classified according to revised European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria. A receiver operator characteristic (ROC) curve was generated; possible causes for false-positive and false-negative tests were investigated by linear regression analysis. Seven hundred fifty-six serum specimens from 59 subjects without IFI and 41 specimens from 14 patients with proven or probable IFI were tested. The area under the ROC curve was 0.69. Based on a 60-pg/ml positive cutoff, per-patient sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 64%, 9%, 14%, and 50%, respectively; per-test estimates were 71%, 59%, 9%, and 97%, respectively. The majority (92%) of patients not diagnosed with an IFI had at least one BG level of ≥60 pg/ml, and 90% had at least one BG level of ≥80 pg/ml. Respiratory colonization with mold and hemodialysis significantly affected mean BG levels. In conclusion, the accuracy of the BG test is marginal and its utility as a tool for the early diagnosis of IFI is questionable in the lung transplant population. Although the NPV of the BG test is high, the low PPV limits its utility as a screening tool for early diagnosis of IFI.
- Published
- 2010
- Full Text
- View/download PDF
22. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update.
- Author
-
Wilson DT, Drew RH, and Perfect JR
- Subjects
- Amphotericin B therapeutic use, Drug Therapy, Combination, Echinocandins therapeutic use, Humans, Mycoses etiology, Transplantation, Homologous, Triazoles therapeutic use, Antifungal Agents therapeutic use, Mycoses drug therapy, Stem Cell Transplantation adverse effects
- Abstract
Invasive fungal diseases (IFDs) remain a major cause of morbidity and mortality in allogeneic stem cell transplant (SCT) recipients. While the most common pathogens are Candida spp. and Aspergillus spp., the incidence of infections caused by non-albicans Candida species as well as molds such as Zygomycetes has increased. For many years, amphotericin B deoxycholate (AMB-D) was the only available antifungal for the treatment of IFDs. Within the past decade, there has been a surge of new antifungal agents developed and added to the therapeutic armamentarium. Lipid-based formulations of amphotericin B provide an effective and less nephrotoxic alternative to AMB-D. Voriconazole has now replaced AMB-D as first choice for primary therapy of invasive aspergillosis (IA). Another extended-spectrum triazole, posaconazole, also appears to be a promising agent in the management of zygomycosis, refractory aspergillosis, and for prophylaxis. Members of the newest antifungal class, the echinocandins, are attractive agents in select infections due to their safety profile, and are a more attractive option compared to AMB-D as initial treatment for invasive candidiasis and (based on one study) challenge fluconazole for superiority in management with this mycoses. However, challenges do exist among these newer agents in very high-risk individuals like allogeneic SCT recipients, which may include adverse drug events, drug-drug interactions, variability in oral absorption, and availability of alternative formulations. The addition of newer agents has also stimulated interest in the potential application of combination therapy in serious, life-threatening infections. However, adequate studies are not available for most IFDs; thus, the clinical use of combination therapy is not evidenced based on most cases and preciseness in its use is uncertain. Finally, therapeutic drug monitoring of select antifungals (notably posaconazole and voriconazole) may play an increasing role due to significant interpatient variability in serum concentrations after standard doses.
- Published
- 2009
- Full Text
- View/download PDF
23. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients.
- Author
-
Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, and Papadopoulos G
- Subjects
- Adolescent, Adult, Age Factors, Aged, Female, Humans, Length of Stay economics, Male, Middle Aged, Retrospective Studies, Risk Factors, Sex Factors, Socioeconomic Factors, Young Adult, Health Status, Hospital Costs statistics & numerical data, Length of Stay statistics & numerical data, Mycoses economics, Mycoses mortality
- Abstract
Purpose: The mortality, length of hospitalization, and costs associated with invasive fungal infections (IFIs) in hospitalized patients were studied., Methods: This retrospective database study used data from the 2004 Healthcare Cost and Utilization Project Nationwide In-patient Sample. Patients were selected for inclusion based on diagnostic codes corresponding to an IFI. A control group was matched to the IFI group based on high-risk conditions (i.e., cancer, infection with human immunodeficiency virus, chronic obstructive pulmonary disease, diabetes mellitus, and solid-organ, hematopoietic stem cell, or bone marrow transplant), age, sex, and hospital region and teaching status. Excess mortality, length of hospital stay, and costs were estimated as the differences between the IFI and control groups., Results: A total of 11,881 patients were identified with a discharge diagnosis of an IFI who could be matched to a control. Frequent infections included candidiasis (40.2%), other mycoses (36.3%), and aspergillosis (16.4%). Patients with IFIs had a significantly higher mortality rate (15% versus 5%), mean +/- S.E. length of stay (18.7 +/- 0.4 days versus 7.3 +/- 0.1 days), and mean +/- S.E. costs ($44,726 +/- $1,255 versus $15,445 +/- $404) (p < 0.001 for all comparisons) than did patients without IFIs. The burden of IFIs varied by high-risk condition (highest for transplant recipients and patients with cancer) and type of infection (highest for candidiasis, zygomycosis, and aspergillosis)., Conclusion: Examination of a large database showed that, compared with high-risk patients without IFIs, those with IFIs had higher mortality, a longer hospital stay, and higher costs associated with their hospitalization.
- Published
- 2009
- Full Text
- View/download PDF
24. Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis.
- Author
-
Naggie S and Perfect JR
- Subjects
- Humans, Mycoses diagnosis, Zygomycosis
- Abstract
Emerging fungi previously thought to be nonpathogenic are now recognized as playing a significant role in the increased incidence of invasive fungal disease. This change in the epidemiology of invasive fungal infections (IFIs) has occurred in the era of aggressive new therapies for hematopoietic stem cell transplantation and other malignancies that lead to profound immunosuppression for longer durations and has extended the survival of these critically ill patients. The significant morbidity and mortality associated with these infections is not only related to the host populations but to delayed recognition and diagnosis and high rates of resistance in some of these emerging pathogens to standard antifungal therapies.
- Published
- 2009
- Full Text
- View/download PDF
25. Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.
- Author
-
Smith WJ, Drew RH, and Perfect JR
- Subjects
- Animals, Antifungal Agents adverse effects, Antifungal Agents pharmacology, Disease Models, Animal, Drug Dosage Calculations, Drug Interactions, Drug Resistance, Fungal, Humans, Microbial Sensitivity Tests, Mycoses prevention & control, Triazoles adverse effects, Triazoles pharmacology, Antifungal Agents therapeutic use, Mycoses drug therapy, Triazoles therapeutic use
- Abstract
Owing to the morbidity and mortality associated with invasive fungal infections, particularly in the immunocompromised host, development of new agents for both prevention and treatment is essential. Posaconazole is a recently approved extended-spectrum triazole available as an oral suspension. It exhibits fungistatic activity against a variety of fungal pathogens. Pharmacokinetic data in special patient populations (such as neutropenic patients with acute myelogenous leukemia or myelodysplastic syndrome, allogeneic hematopoietic stem cell transplant recipients, febrile neutropenic patients and pediatric patients) have been published recently. Controlled clinical trials establish posaconazole's safety and efficacy in infections, such as oropharyngeal candidiasis and prophylaxis against invasive fungal infections. Data are also emerging in the treatment of zygomycosis and selected cases of aspergillosis. Posaconazole is well tolerated during short- and long-term use, with the most commonly reported adverse events being mild-to-moderate gastrointestinal disturbances. Data suggest a relationship between posaconazole plasma concentrations and prophylactic efficacy; however, the role of therapeutic drug monitoring has yet to be completely defined. Since posaconazole is available only as an oral formulation, its use may be limited in critically ill patient populations.
- Published
- 2009
- Full Text
- View/download PDF
26. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease.
- Author
-
Cowen LE, Singh SD, Köhler JR, Collins C, Zaas AK, Schell WA, Aziz H, Mylonakis E, Perfect JR, Whitesell L, and Lindquist S
- Subjects
- Animals, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Fluconazole pharmacology, Fluconazole therapeutic use, Fungi drug effects, HSP90 Heat-Shock Proteins genetics, Humans, Male, Mice, Microbial Sensitivity Tests, Mycoses drug therapy, Mycoses microbiology, Mycoses physiopathology, HSP90 Heat-Shock Proteins physiology, Mycoses therapy
- Abstract
Invasive fungal infections are a leading cause of mortality among immunocompromised individuals. Treatment is notoriously difficult with the limited armamentarium of antifungal drugs, whose efficacy is compromised by host toxicity, a limited activity spectrum, or the emergence of drug resistance. We previously established that the molecular chaperone Hsp90 enables the emergence and maintenance of fungal drug resistance. For the most prevalent fungal pathogen of humans, Candida albicans, Hsp90 mediates resistance to azoles, which inhibit ergosterol biosynthesis and are the most widely deployed antifungals in the clinic. For the emerging opportunistic pathogen Aspergillus terreus, Hsp90 is required for basal resistance to echinocandins, which inhibit beta(1, 3)-glucan synthesis and are the only new class of antifungals to reach the clinic in decades. Here, we explore the therapeutic potential of Hsp90 inhibitors in fungal disease using a tractable host-model system, larvae of the greater wax moth Galleria mellonella, and a murine model of disseminated disease. Combination therapy with Hsp90 inhibitors that are well tolerated in humans and an azole rescued larvae from lethal C. albicans infections. Combination therapy with an Hsp90 inhibitor and an echinocandin rescued larvae from infections with the most lethal mold, Aspergillus fumigatus. In a murine model of disseminated candidiasis, genetic compromise of C. albicans HSP90 expression enhanced the therapeutic efficacy of an azole. Thus, harnessing Hsp90 provides a much-needed strategy for improving the treatment of fungal disease because it enhances the efficacy of existing antifungals, blocks the emergence of drug resistance, and exerts broad-spectrum activity against diverse fungal pathogens.
- Published
- 2009
- Full Text
- View/download PDF
27. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant.
- Author
-
Alexander BD, Perfect JR, Daly JS, Restrepo A, Tobón AM, Patino H, Hardalo CJ, and Graybill JR
- Subjects
- Adult, Aged, Aspergillosis drug therapy, Candidiasis drug therapy, Female, Humans, Immunosuppressive Agents therapeutic use, Incidence, Male, Middle Aged, Mycoses epidemiology, Postoperative Complications drug therapy, Postoperative Complications microbiology, Retrospective Studies, Safety, Treatment Outcome, Antifungal Agents therapeutic use, Mycoses drug therapy, Organ Transplantation adverse effects, Triazoles therapeutic use
- Abstract
Background: The incidence of invasive fungal infections (IFIs) in solid organ transplant (SOT) recipients has increased during the past 20 years and is associated with significant morbidity and mortality. In this post hoc analysis of a large, open-label, multicenter study, we evaluated efficacy and safety of posaconazole, a new extended-spectrum triazole, as salvage therapy for IFIs in SOT recipients., Methods: Twenty-three SOT recipients with proven or probable IFI and evidence of disease refractory to, or intolerant of, standard antifungal therapies received posaconazole oral suspension (40 mg/mL) 800 mg daily in divided doses. An independent, blinded data-review committee assessed patient diagnosis and outcome., Results: Complete or partial response was documented in 13 of 23 (57%) SOT recipients with proven or probable IFIs, including 1 of 2 (50%) refractory patients, 5 of 8 (63%) intolerant to prior therapy, and 7 of 13 (54%) who were both. Successes by type of IFI included 7 of 12 with invasive aspergillosis, 2 of 2 with invasive fusariosis, 1 of 1 with cryptococcosis, and 1 of 2 with zygomycosis. Treatment-related adverse events (TRAEs) were reported in 12 of 23 patients. Severe TRAEs occurred in 4 of 23 patients including increased levels of cyclosporine or tacrolimus requiring immunosuppressive dose adjustments in three patients and in one, termination of posaconazole. Severe TRAEs associated with renal and liver toxicities were uncommon., Conclusion: Posaconazole was well tolerated and effective against IFIs including invasive aspergillosis, zygomycosis, fusariosis, and cryptococcosis in SOT recipients intolerant of or failing other antifungal therapies. Calcineurin inhibitor levels should be closely monitored in patients treated concomitantly with posaconazole to avoid toxicity from drug interaction.
- Published
- 2008
- Full Text
- View/download PDF
28. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
- Author
-
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, and Bennett JE
- Subjects
- Humans, Mycoses classification, Mycoses diagnosis, Terminology as Topic
- Abstract
Background: Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies., Methods: After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved., Results: The revised definitions retain the original classifications of "proven," "probable," and "possible" invasive fungal disease, but the definition of "probable" has been expanded, whereas the scope of the category "possible" has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only., Conclusions: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
- Published
- 2008
- Full Text
- View/download PDF
29. When primary antifungal therapy fails.
- Author
-
Nucci M and Perfect JR
- Subjects
- Humans, Mycoses diagnosis, Treatment Failure, Antifungal Agents therapeutic use, Mycoses drug therapy
- Abstract
The prognosis for persons with invasive fungal infections has improved over the past 2 decades because of the development of new diagnostic tools, a better understanding of the epidemiology and prognostic factors of these infections, and the availability of new antifungal agents. Nevertheless, antifungal therapy failure is still a substantial clinical problem. When this occurs, the clinician is tempted to attribute therapeutic failure to specific drug resistance and then to change therapy or add another antifungal drug to the regimen. However, other factors may play an even greater role in antifungal therapy failure, such as host factors, low concentration of the drug at the site of infection, drug toxicities, wrong diagnosis, and misdiagnosis of failure because of the occurrence of immune reconstitution inflammatory syndrome. In this review, we discuss the differential diagnosis and management of antifungal therapy failure in invasive mycoses, to help clinicians appreciate the meaning of primary antifungal therapy failure.
- Published
- 2008
- Full Text
- View/download PDF
30. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.
- Author
-
Kanafani ZA and Perfect JR
- Subjects
- Humans, Immunocompromised Host, Microbial Sensitivity Tests methods, Mycoses microbiology, Antifungal Agents pharmacology, Drug Resistance, Fungal, Mycoses drug therapy
- Abstract
Despite advances in preventive, diagnostic, and therapeutic interventions, invasive fungal infections cause significant morbidity and mortality in immunocompromised patients. The burden of antifungal resistance in such high-risk patients is becoming a major concern. A better understanding of the mechanisms and clinical impact of antifungal resistance is essential to the prompt and efficient treatment of patients with invasive mycoses and to improving the outcome of such infections. Although recent guidelines have attempted to standardize antifungal susceptibility testing, limitations still exist as a result of the incomplete correlation between in vitro susceptibility and clinical response to treatment. Four major mechanisms of resistance to azoles have been identified, all of which rely on altered gene expression. Mechanisms responsible for polyene and echinocandin resistance are less well understood. In addition to discussing the molecular mechanisms of antifungal resistance, this article elaborates on the concept of clinical resistance, which is critical to the understanding of treatment failure in patients with invasive fungal infections.
- Published
- 2008
- Full Text
- View/download PDF
31. Combination antifungal therapy: what can and should we expect?
- Author
-
Johnson MD and Perfect JR
- Subjects
- Drug Therapy, Combination, Evidence-Based Medicine, Humans, Immunocompromised Host, Randomized Controlled Trials as Topic, Antifungal Agents therapeutic use, Hematopoietic Stem Cell Transplantation adverse effects, Mycoses drug therapy
- Abstract
Invasive fungal infections are associated with significant morbidity and mortality among immunocompromised patients. Recent advances in antifungal development have afforded us more pharmacologic compounds to choose from when managing these fungal infections. The role of combination antifungal therapy has been well established for fungal infections such as cryptococcal meningitis. The availability of new antifungals, increased incidence of mould infections and high mortality among certain affected populations, such as hematopoietic stem cell transplant recipients, has stimulated interest in the clinical use of combination antifungal therapy. In this paper, we review supporting evidence for the use of combination antifungals in the treatment of cryptococcal meningitis, invasive candidiasis, invasive aspergillosis and zygomycosis. Several controlled clinical trials have demonstrated benefits of combination antifungal approaches for patients with cryptococcal meningitis and invasive candidiasis, but variable effects when using different agents in combination have been reported. Randomized prospective studies of combination antifungal therapy in mould infections are lacking but some series provide supportive evidence for this approach. We also describe limitations of the data and these study designs, including the fact that we still need randomized controlled multicenter studies of combination antifungal therapy for mould infections. Trials in this area should be performed with efficiency and economics in mind, and could potentially use surrogate markers as end points. Therefore, we suggest future investigations of combination antifungal therapy should include a randomized, comparative trial of primary therapy for invasive aspergillosis.
- Published
- 2007
- Full Text
- View/download PDF
32. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
- Author
-
Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, and Heitman J
- Subjects
- Calcineurin chemistry, Fungi drug effects, Humans, Mycoses microbiology, Signal Transduction, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Calcineurin physiology, Calcineurin Inhibitors, Fungi physiology, Mycoses drug therapy
- Abstract
The number of immunocompromised patients with invasive fungal infections continues to increase and new antifungal therapies are not keeping pace with the growing incidence of these infections and their associated mortality. Calcineurin inhibition is currently used to exert effective immunosuppression following organ transplantation and in treating various other conditions. However, the calcineurin pathway is also intricately involved in the growth and pathogenesis of the three major fungal pathogens of humans, Cryptococcus neoformans, Candida albicans and Aspergillus fumigatus, and the exploitation of fungal calcineurin pathways holds great promise for the future development of novel antifungal agents. This Review summarizes our current understanding of calcineurin biology in these fungal species, and its exciting potential role in treating invasive fungal infections.
- Published
- 2007
- Full Text
- View/download PDF
33. Immune reconstitution syndrome associated with opportunistic mycoses.
- Author
-
Singh N and Perfect JR
- Subjects
- Adjuvants, Immunologic pharmacology, Humans, Immunocompromised Host drug effects, Immunologic Deficiency Syndromes microbiology, Immunologic Deficiency Syndromes therapy, Recovery of Function immunology, Syndrome, Treatment Failure, Immunocompromised Host immunology, Immunologic Deficiency Syndromes immunology, Mycoses immunology, Mycoses therapy, Opportunistic Infections immunology, Opportunistic Infections therapy
- Abstract
Host immunity is essential in facilitating the eradication of infection. However, immunological recovery and an imbalance characterised by either suboptimum or excessive expression of immune responses can also be harmful to the host. Inflammatory responses triggered by rapid resolution of immunosuppression can lead to a series of localised and systemic reactions, termed immune reconstitution syndrome (IRS), that are often misconstrued as failure of specific antifungal therapy to eliminate the offending fungal pathogen. Recognition of IRS has become increasingly relevant in the context of our current use of potent immunosuppressive agents and immunostimulators that allow rapid manipulation of the immune system. Whereas the conceptual principles of IRS underscore the adverse effects of an overzealous and dysregulated immune response, they also support a role of immunotherapies to augment immunity if induction of endogenous responses is inadequate for the control of infection.
- Published
- 2007
- Full Text
- View/download PDF
34. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
- Author
-
Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, and Wingard JR
- Subjects
- Biomarkers blood, Evaluation Studies as Topic, Fever etiology, Fever microbiology, Fungi pathogenicity, Galactose analogs & derivatives, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Mannans blood, Mycoses diagnosis, Mycoses prevention & control, Neoplasms complications, Neutropenia etiology, Randomized Controlled Trials as Topic, Tomography, X-Ray Computed, Yeasts drug effects, Yeasts pathogenicity, beta-Glucans blood, Antifungal Agents therapeutic use, Fungi drug effects, Mycoses drug therapy, Neoplasms microbiology, Neutropenia microbiology, Practice Guidelines as Topic standards
- Abstract
Invasive fungal infection (IFI) is a leading cause of infection-related mortality among patients with cancer and prolonged neutropenia and among allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Invasive candidiasis was the principal IFI in the period predating fluconazole prophylaxis, whereas today, invasive aspergillosis and other mold infections cause the majority of deaths from fungal infection in this patient population. The changing epidemiology of IFI, in addition to advances made in antifungal therapeutics and early diagnosis of IFI, warrant a reevaluation of earlier strategies aimed at prevention and early treatment of IFI that were developed several years ago. Here, we propose that persistent neutropenic fever is nonspecific for an IFI and should not be used as the sole criterion for empirical modification in the antifungal regimen in a patient receiving mold-active prophylaxis. We explore the potential benefits and gaps in knowledge associated with employing chest CT scans and laboratory markers as diagnostic adjuncts for IFI. Finally, we discuss the implications of newer antifungal agents and diagnostic adjuncts in the design of future clinical trials to evaluate prophylaxis and early prevention strategies.
- Published
- 2007
- Full Text
- View/download PDF
35. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
- Author
-
Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, Negroni R, Perfect JR, Pitisuttithum P, Restrepo A, Schiller G, Pedicone L, and Ullmann AJ
- Subjects
- Adolescent, Adult, Aged, Antifungal Agents therapeutic use, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Triazoles therapeutic use, Antifungal Agents administration & dosage, Antifungal Agents adverse effects, Mycoses drug therapy, Mycoses pathology, Triazoles administration & dosage, Triazoles adverse effects
- Abstract
Background: Invasive fungal infections are found most frequently in immunosuppressed and critically ill hospitalized patients. Antifungal therapy is often required for long periods. Safety data from the clinical development program of the triazole antifungal agent, posaconazole, were analyzed., Methods: A total of 428 patients with refractory invasive fungal infections (n = 362) or febrile neutropenia (n = 66) received posaconazole in 2 phase II/III open-label clinical trials. Also, 109 of these patients received posaconazole therapy for > or = 6 months. Incidences of treatment-emergent, treatment-related, and serious adverse events and abnormal laboratory parameters were recorded during these studies., Results: Treatment-emergent, treatment-related adverse events were reported in 38% of the overall patient population. The most common treatment-related adverse events were nausea (8%) and vomiting (6%). Treatment-related serious adverse events occurred in 8% of patients. Low rates of treatment-related corrected QT interval and/or QT interval prolongation (1%) and elevation of hepatic enzymes (2%) were reported as adverse events. Treatment-emergent, treatment-related adverse events occurred at similar rates in patients who received posaconazole therapy for < 6 months and > or = 6 months., Conclusions: Prolonged posaconazole treatment was associated with a generally favorable safety profile in seriously ill patients with refractory invasive fungal infections. Long-term therapy did not increase the risk of any individual adverse event, and no unique adverse event was observed with longer exposure to posaconazole.
- Published
- 2006
- Full Text
- View/download PDF
36. Emerging echinocandins for treatment of invasive fungal infections.
- Author
-
Turner MS, Drew RH, and Perfect JR
- Subjects
- Animals, Antifungal Agents chemistry, Antifungal Agents pharmacology, Caspofungin, Drug Resistance, Fungal, Drugs, Investigational chemistry, Drugs, Investigational pharmacology, Echinocandins, Humans, Lipopeptides, Mycoses metabolism, Peptides, Cyclic chemistry, Peptides, Cyclic pharmacology, Peptides, Cyclic therapeutic use, Antifungal Agents therapeutic use, Drugs, Investigational therapeutic use, Mycoses drug therapy
- Abstract
The echinocandins are a new class of antifungals, developed in response to the need for safe and effective antifungals for the treatment of invasive fungal infections. These agents work by inhibiting 1,3-beta-d-glucan synthase, an enzyme essential for production of cell walls in select fungi. Echinocandins appear to demonstrate favourable activity in vitro against a variety of yeasts (including both Candida albicans and non-albicans Candida) as well as select moulds (including Aspergillus spp.) In general, all echninocandins demonstrate a favourable safety profile and require once-daily parenteral administration. Caspofungin is the first of these agents to be available in the US, and is approved for empirical antifungal therapy in febrile neutropenic patients, candidaemia and select forms of invasive candidiasis, and for management of invasive aspergillosis in patients refractory to or intolerant of other therapies. Micafungin was recently approved by the FDA for treatment of oesophageal candidiasis, and for the prophylaxis of fungal infections in haematopoietic stem cell transplant recipients. Emerging data indicate micafungin may have an important role in the treatment of invasive forms of candidiasis. Anidulafungin is an echinocandin approved in the US for treatment of candidaemia and oesophageal candidiasis. Aminocandin (HMR-3702, IP-960) is an investigational agent, with published experience limited to in vitro studies and animal models of infection.
- Published
- 2006
- Full Text
- View/download PDF
37. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
- Author
-
Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, and Perfect JR
- Subjects
- Adolescent, Adult, Aerosols, Amphotericin B adverse effects, Antifungal Agents adverse effects, Drug Combinations, Drug Therapy, Combination, Female, Fluconazole therapeutic use, Humans, Male, Middle Aged, Phosphatidylcholines adverse effects, Phosphatidylglycerols adverse effects, Safety, Transplantation, Homologous, Treatment Outcome, Amphotericin B therapeutic use, Antifungal Agents therapeutic use, Hematopoietic Stem Cell Transplantation, Mycoses prevention & control, Phosphatidylcholines therapeutic use, Phosphatidylglycerols therapeutic use
- Abstract
Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at increased risk for invasive fungal infections (IFIs) over prolonged periods of time. Aerosolized amphotericin B lipid complex (ABLC) has shown promise in lung transplant recipients as a convenient means of delivering protective drug to the upper airways avoiding systemic toxicities. The safety and tolerability of aerosolized ABLC in 40 subjects undergoing allogeneic HSCT was prospectively investigated in an open-labeled, non-comparative study. Subjects received aerosolized ABLC treatment once daily for 4 days, then once weekly for 13 weeks; fluconazole was administered daily as standard of care through post-transplant day 100. Pulmonary mechanics were measured before and after each dose of inhaled ABLC; adverse events (AEs) and the development of IFI were also monitored. Cough, nausea, taste disturbance, or vomiting followed 2.2% of 458 total inhaled ABLC administrations; 5.2% of inhaled ABLC administrations were associated with >or=20% decrease in pulmonary function measurements (forced expiratory volume in 1 second or forced vital capacity) and none required treatment with bronchodilators or withdrawal from study. Four mild AEs were considered possibly or probably related to study treatment; no deaths or withdrawals from treatment were attributed to study drug. Of 3 proven IFIs occurring during the study period, only 1, a catheter-related case of disseminated fusariosis, occurred while the subject was receiving study medication. Aerosolized ABLC was well tolerated in allogeneic HSCT recipients. With only 1 of 40 subjects developing IFI while receiving treatment, the combination of fluconazole and inhaled ABLC warrants further study as antifungal prophylaxis following allogeneic HSCT.
- Published
- 2006
- Full Text
- View/download PDF
38. Novel use of a swimming pool biocide in the treatment of a rare fungal mastoiditis.
- Author
-
Chang CY, Schell WA, Perfect JR, and Hulka GF
- Subjects
- Child, Humans, Immunocompromised Host, Male, Mastoiditis surgery, Mycoses surgery, Swimming Pools, Water Microbiology, Biguanides therapeutic use, Disinfectants therapeutic use, Mastoiditis drug therapy, Mycoses drug therapy
- Abstract
Objective: To describe an extremely rare fungal mastoiditis caused by Lecythophora hoffmannii, its recalcitrant behavior to therapy, and eventual successful treatment with adjunctive therapy using polyhexamethylene biguanide (a common swimming pool biocide)., Study Design: Case report and review of literature of human Lecythophora hoffmannii infections., Methods: Medline database was searched using the keywords Lecythophora and hoffmannii. All articles that described Lecythophora hoffmannii as the cause of human infection at any site were identified. Literature and patient's records were considered for complete data review and extraction., Results: We present the second known case in the literature of a human infection with Lecythophora hoffmannii. We also present the process to definitively identify and then to successfully eradicate this unusual fungal infection using polyhexamethylene biguanide as adjunctive treatment., Conclusions: Successful treatment of a chronic Lecythophora hoffmannii fungal mastoiditis involved a combination of radical surgical removal of all apparent infected tissue along with local treatments with polyhexamethylene biguanide, a common swimming pool biocide agent under the brand name Baquacil (Avecia, Manchester, United Kingdom). Given the prolonged course of treatment, this report particularly stresses the importance of concurrent surgery combined with creative local antimicrobial therapy to eliminate an unusual fungal infection in an immunocompetent host.
- Published
- 2005
- Full Text
- View/download PDF
39. Is it time to abandon the use of amphotericin B bladder irrigation?
- Author
-
Drew RH, Arthur RR, and Perfect JR
- Subjects
- Humans, Mycoses microbiology, Urinary Tract Infections microbiology, Amphotericin B therapeutic use, Antifungal Agents therapeutic use, Mycoses drug therapy, Urinary Catheterization, Urinary Tract Infections drug therapy
- Abstract
In this article, we review the issues surrounding funguria and its management. With this background, the value of bladder irrigation with amphotericin B for the management of funguria is directly examined. Amphotericin B bladder irrigation is used frequently in clinical practice. Although its use is not standardized, there are multiple studies that attempt to show the impact on funguria management. These bladder irrigations have been used either for treatment of funguria or (less commonly) as a diagnostic test in attempts to identify upper urinary tract disease. Despite their widespread therapeutic use and relative safety, it is not clear from our experience and a review of the literature that amphotericin B bladder irrigations have any diagnostic or therapeutic value. The patient may be best served by removal of the urinary catheter, if possible, rather than by instillation of bladder irrigation with amphotericin B.
- Published
- 2005
- Full Text
- View/download PDF
40. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.
- Author
-
Perfect JR
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B adverse effects, Antifungal Agents adverse effects, Child, Child, Preschool, Drug Combinations, Female, Fusarium, Humans, Infant, Kidney drug effects, Male, Middle Aged, Phosphatidylcholines adverse effects, Phosphatidylglycerols adverse effects, Registries, Retrospective Studies, Treatment Outcome, Zygomycosis drug therapy, Amphotericin B therapeutic use, Antifungal Agents therapeutic use, Immunocompromised Host, Mycoses drug therapy, Opportunistic Infections drug therapy, Phosphatidylcholines therapeutic use, Phosphatidylglycerols therapeutic use
- Abstract
An assessment was made of the efficacy and renal safety of amphotericin B lipid complex (ABLC) in the treatment of patients with invasive fungal infections caused by moulds other than Aspergillus species, on the basis of a retrospective analysis of data from the Collaborative Exchange of Antifungal Research (CLEAR) database. Data from CLEAR for 64 patients with zygomycosis were published previously. The database was further queried and yielded results for 28 patients with fusariosis and 84 patients infected with other non-Aspergillus moulds. Of 26 patients with fusariosis whose results could be evaluated, 46% (n = 12) were cured or improved, and an additional 12% (n = 3) were stable. Of 79 patients infected with other non-Aspergillus moulds whose results could be evaluated, 61% (n = 48) were cured or improved, and an additional 15% (n = 12) were stable. In an area with little guidance for therapy, the CLEAR data indicate that ABLC can be an effective broad-spectrum treatment choice for several invasive and refractory non-Aspergillus mould infections.
- Published
- 2005
- Full Text
- View/download PDF
41. Management of invasive mycoses in hematology patients: current approaches.
- Author
-
Perfect JR
- Subjects
- Amphotericin B therapeutic use, Aspergillosis drug therapy, Candidiasis drug therapy, Deoxycholic Acid therapeutic use, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Drug Resistance, Fungal, Echinocandins, Fungal Proteins therapeutic use, Humans, Liposomes, Mycoses etiology, Neutropenia chemically induced, Peptides, Cyclic therapeutic use, Randomized Controlled Trials as Topic, Survival Analysis, Triazoles therapeutic use, Antifungal Agents therapeutic use, Hematopoietic Stem Cell Transplantation adverse effects, Mycoses drug therapy, Neoplasms therapy
- Abstract
Candidiasis and aspergillosis are the most common fungal infections in hematopoietic stem cell transplant recipients and other hematology/oncology patients. Strategies for reducing the morbidity and mortality associated with these infections include antifungal prophylaxis, empiric therapy in patients with persistent fever and neutropenia, and preemptive therapy. Antifungal therapies include amphotericin B deoxycholate, lipid formulations of amphotericin B, the triazoles (fluconazole, itraconazole, and voriconazole), and the echinocandins (caspofungin and the investigational agents micafungin and anidulafungin). Fluconazole is a reasonable choice for the treatment of invasive candidiasis if the patient has not previously received a triazole and the institution has a low incidence of triazole resistance. If resistance is a concern, an echinocandin, such as caspofungin, is an appropriate option. Voriconazole may be the initial choice in most patients with invasive aspergillosis. If patients are intolerant of or refractory to conventional therapy, effective alternatives include a lipid formulation of amphotericin B or an echinocandin.
- Published
- 2004
42. Use of newer antifungal therapies in clinical practice: what do the data tell us?
- Author
-
Perfect JR
- Subjects
- Amphotericin B therapeutic use, Aspergillosis drug therapy, Candidiasis drug therapy, Caspofungin, Deoxycholic Acid therapeutic use, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Drug Resistance, Fungal, Echinocandins, Humans, Lipopeptides, Liposomes, Peptides, Cyclic therapeutic use, Phosphatidylcholines therapeutic use, Phosphatidylglycerols therapeutic use, Pyrimidines therapeutic use, Randomized Controlled Trials as Topic, Time Factors, Treatment Outcome, Triazoles therapeutic use, Voriconazole, Zygomycosis drug therapy, Antifungal Agents therapeutic use, Mycoses drug therapy
- Abstract
Considering the significant morbidity and mortality associated with invasive fungal infections in immunocompromised patients, it is particularly important to make the diagnosis as early as possible and to make best use of the available antifungal drugs for prophylaxis and treatment. The newer antifungal drugs include the lipid products of amphotericin B, such as amphotericin B lipid complex (ABLC) and liposomal amphotericin B; voriconazole (a triazole); and caspofungin (an echinocandin). ABLC and liposomal amphotericin B are as effective as amphotericin B deoxycholate but are less nephrotoxic; ABLC is probably the drug of choice for zygomycosis. Voriconazole is approved for use in the treatment of invasive aspergillosis and may have a role in preventing breakthrough fungal infections in patients with persistent fever and neutropenia. Caspofungin is effective against both invasive aspergillosis and invasive candidiasis.
- Published
- 2004
43. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients.
- Author
-
Perfect JR, Dodds Ashley E, and Drew R
- Subjects
- Aerosols therapeutic use, Antifungal Agents administration & dosage, Clinical Trials as Topic, Drug Combinations, Humans, Immunocompromised Host immunology, Transplantation, Amphotericin B therapeutic use, Antifungal Agents therapeutic use, Deoxycholic Acid therapeutic use, Lung Transplantation adverse effects, Mycoses prevention & control, Preventive Medicine, Research Design
- Abstract
Background: Emphasis has been placed on the need for antifungal prophylaxis when transplanted organs are directly exposed to the environment. In lung transplantation, one strategy for prevention has been aerosolization of polyenes into the lung. Despite widespread use of amphotericin B aerosols, there are still few studies on how to validate their effectiveness or optimize pharmacokinetics., Methods: We compared results of several of our own studies of lung transplant recipients receiving formulations of amphotericin B with results of other studies., Results: Recent aerosol studies suggest that aerosols of a lipid formulation of amphotericin B are safe and better tolerated than is amphotericin B deoxycholate. Their use in prophylaxis is associated with very few pulmonary fungal infections., Conclusion: This safe drug delivery at a local body site to directly protect the transplanted organ without systemic antifungal drug exposure is attractive from a cost and toxicity standpoint. However, careful multicenter, comparative studies are still needed to ensure that this strategy is consistently successful.
- Published
- 2004
- Full Text
- View/download PDF
44. Recent advances in antifungal pharmacotherapy for invasive fungal infections.
- Author
-
Gallagher JC, MacDougall C, Ashley ES, and Perfect JR
- Subjects
- Amphotericin B pharmacology, Amphotericin B therapeutic use, Antifungal Agents pharmacology, Aspergillus drug effects, Candida drug effects, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Mycoses microbiology, Antifungal Agents therapeutic use, Mycoses drug therapy
- Abstract
Invasive fungal infections carry significant morbidity and mortality. Candida species have become one of the most frequent causes of bloodstream infections, and infections caused by molds such as Aspergillus are becoming more frequent in immunocompromised patients. As this population grows, more invasive fungal infections can be anticipated. In the past, treatment options have been limited for many of these infections due to toxicity and efficacy concerns with the available antifungals. Fortunately, the past few years have brought exciting developments in antifungal pharmacotherapy. Lipid-based formulations of amphotericin B were introduced in the 1990s to attenuate adverse effects caused by amphotericin B deoxycholate (Fungizone, Bristol-Myers Squibb). Most recently, the echinocandins have been added to our antifungal regimen with the introduction of caspofungin (Cancidas, Merck and Co.) and voriconazole (Vfend, Pfizer), a new triazole, has come to market. The introduction of the echinocandins has invigorated the discussion about combination antifungal therapy. Evidence-based studies using these new agents are accumulating, and they are assuming important roles in the pharmacotherapy of invasive fungal infections in seriously ill and complex patients.
- Published
- 2004
- Full Text
- View/download PDF
45. Combination antifungal therapy.
- Author
-
Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, and Rex JH
- Subjects
- Animals, Antifungal Agents pharmacology, Drug Combinations, Drug Interactions, Fungi drug effects, Humans, Antifungal Agents therapeutic use, Mycoses drug therapy
- Published
- 2004
- Full Text
- View/download PDF
46. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.
- Author
-
Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, and Perfect JR
- Subjects
- Adolescent, Adult, Aerosols, Aged, Amphotericin B administration & dosage, Amphotericin B adverse effects, Deoxycholic Acid administration & dosage, Deoxycholic Acid adverse effects, Double-Blind Method, Drug Combinations, Female, Heart-Lung Transplantation physiology, Humans, Lung Diseases classification, Lung Diseases surgery, Male, Middle Aged, Phosphatidylcholines administration & dosage, Phosphatidylcholines adverse effects, Phosphatidylglycerols administration & dosage, Phosphatidylglycerols adverse effects, Racial Groups, Retrospective Studies, Amphotericin B therapeutic use, Deoxycholic Acid therapeutic use, Lung Transplantation physiology, Mycoses prevention & control, Phosphatidylcholines therapeutic use, Phosphatidylglycerols therapeutic use, Postoperative Complications prevention & control
- Abstract
Background: Aerosolized administrations of amphotericin B deoxycholate (AmBd) and amphotericin B lipid complex (ABLC) in lung transplant recipients were compared for safety and tolerability. The incidence of invasive fungal infections in patients receiving aerosolized amphotericin B formulations as sole prophylaxis was determined., Methods: A prospective, randomized (1:1), double-blinded trial was conducted with 100 subjects. AmBd and ABLC were administered postoperatively by nebulizer at doses of 25 mg and 50 mg, respectively, which were doubled in mechanically ventilated patients. The planned treatment was once every day for 4 days, then once per week for 7 weeks. Treatment-related adverse events and invasive fungal infections were quantitated for 2 months after study drug initiation., Results: Intent-to-treat analysis revealed study drug was discontinued for intolerance in 6 of 49 (12.2%) and 3 of 51 (5.9%) patients in the AmBd- and ABLC-treated groups, respectively (p=0.313). Subjects receiving AmBd were more likely to have experienced an adverse event (odds ratio 2.16, 95% confidence interval 1.10, 4.24, p=0.02). Primary prophylaxis failure within 2 months of study drug initiation was observed in 7 of 49 (14.3%) AmBd-treated patients and 6 of 51 (11.8%) ABLC-treated patients. No fungal pneumonias were observed. Only two (2%) patients experienced documented primary prophylaxis failure with Aspergillus infections within the follow-up period., Conclusions: Both aerosol AmBd and ABLC appear to be associated with a low rate of invasive pulmonary fungal infection in the early posttransplant period. Patients receiving ABLC were less likely to experience a treatment-related adverse event.
- Published
- 2004
- Full Text
- View/download PDF
47. Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients.
- Author
-
Steinbach WJ, Schell WA, Miller JL, Perfect JR, and Martin PL
- Subjects
- Antifungal Agents therapeutic use, Caspofungin, Child, Echinocandins, Fatal Outcome, Humans, Lipopeptides, Male, Mycoses drug therapy, Opportunistic Infections drug therapy, Peptides therapeutic use, Pyrimidines therapeutic use, Triazoles therapeutic use, Voriconazole, Immunocompromised Host, Mitosporic Fungi, Mycoses microbiology, Opportunistic Infections microbiology, Peptides, Cyclic, Stem Cell Transplantation
- Published
- 2004
- Full Text
- View/download PDF
48. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates.
- Author
-
Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, and Perfect JR
- Subjects
- Humans, Microbial Sensitivity Tests, Rhodotorula isolation & purification, Antifungal Agents pharmacology, Mycoses microbiology, Rhodotorula drug effects, Rhodotorula pathogenicity
- Abstract
Rhodotorula infections occur among patients with immunosuppression and/or central venous catheters. Using standardized methods (NCCLS M27-A), we determined the antifungal susceptibilities of 10 Rhodotorula bloodstream infection isolates. Patient information was collected for clinical correlation. The MICs of amphotericin B and posaconazole were the lowest, and the MICs of triazoles and echinocandins were higher than those of other antifungal agents.
- Published
- 2003
- Full Text
- View/download PDF
49. Caspofungin: first approved agent in a new class of antifungals.
- Author
-
Johnson MD and Perfect JR
- Subjects
- Adult, Aged, Animals, Area Under Curve, Aspergillosis drug therapy, Biological Availability, Candidiasis drug therapy, Caspofungin, Disease Models, Animal, Drug Interactions, Echinocandins, Female, Half-Life, Humans, Lipopeptides, Male, Microbial Sensitivity Tests, Tissue Distribution, Anti-Bacterial Agents metabolism, Anti-Bacterial Agents pharmacokinetics, Anti-Bacterial Agents therapeutic use, Antifungal Agents metabolism, Antifungal Agents pharmacokinetics, Antifungal Agents therapeutic use, Mycoses drug therapy, Peptides, Peptides, Cyclic
- Abstract
Caspofungin (Cancidas, Merck & Co. Inc.) is the first echinocandin antifungal agent to gain FDA-approval for use in the US. It has excellent clinical activity against Candida spp. and Aspergillus spp. but lacks significant activity against Cryptococcus neoformans. Caspofungin may have some activity against dimorphic fungi such as Histoplasma capsulatum and Coccidioides immitis, but no clinical data is available for treatment of these infections. Caspofungin has demonstrated poor activity against most filamentous fungi in vitro. Several clinical trials have demonstrated its efficacy in the treatment of oropharyngeal, oesophageal and invasive candidiasis, as well as invasive aspergillosis. As a result of caspofungin's unique mechanism of action, and the high morbidity and mortality of invasive fungal infections, there is considerable interest in using this new antifungal agent as part of a combination antifungal therapy. In vitro studies and small case series indicate that caspofungin does not appear to be antagonistic when combined with other antifungals, such as itraconazole, voriconazole or amphotericin B against Aspergillus spp. Caspofungin exerts concentration-dependent killing effects in many different in vitro and animal models of disseminated fungal infection. The usual daily dose is 50 mg/day i.v. following a 70 mg i.v. loading dose. However, higher caspofungin doses have been safely administered and up to 70 mg/day can be administered for patients who fail to respond to lower doses. Caspofungin has an excellent safety profile with reduced toxicities, compared to other licensed antifungal agents. Fever, thrombophlebitis, headache and liver enzyme elevations were the most common drug-related side effects reported in clinical trials so far. Additional data are needed to document its safety in long-term use, and with higher doses in patients with invasive fungal infections. Caspofungin is a promising agent as first-line therapy for invasive candidiasis, and as salvage therapy for invasive aspergillosis. However, more clinical data are needed to define its role as primary therapy for invasive aspergillosis, and its role in combination antifungal therapy.
- Published
- 2003
- Full Text
- View/download PDF
50. Newer antifungal therapy for emerging fungal pathogens.
- Author
-
Steinbach WJ and Perfect JR
- Subjects
- Animals, Antifungal Agents pharmacology, Fungi classification, Fungi drug effects, Fungi isolation & purification, Fungi physiology, Humans, Mycoses microbiology, Antifungal Agents therapeutic use, Communicable Diseases, Emerging drug therapy, Communicable Diseases, Emerging microbiology, Mycoses drug therapy
- Abstract
As the number of immunocompromised patients increases, there is a concomitant increase in the number and diversity of fungal infections. Fungi that were once considered harmless or contaminants are now pathogenic in the immunocompromised host. Often these emerging pathogens are indistinguishable from the more familiar fungal infections; however, they are generally more recalcitrant to conventional antifungal therapies. With the antifungal armamentarium now expanding, the clinician now has many more options for these difficult-to-treat mycoses. We review many of the newer antifungal agents (second-generation triazoles, echinocandins, etc.) as therapeutic options for the recently emerging fungal pathogens.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.